Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
about
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsFactors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South AfricaInitiating antiretrovirals during tuberculosis treatment: a drug safety review.TB and HIV Therapeutics: Pharmacology Research Priorities.Unresolved antiretroviral treatment management issues in HIV-infected childrenVirologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, EthiopiaPopulation pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Tackling virological failure in HIV-infected children living in Africa.Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV Infected Children and the Effect on Treatment Outcomes.Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition
P2860
Q28069383-0423CE85-A6F5-4834-B8AD-9716C27CAB78Q28546698-50442C74-0603-422D-89D5-97F5271A849AQ35043048-A4E372D8-084F-4941-8A93-8CE29B0A2DF5Q36099838-69FEAC06-EE8F-446F-9F55-BB64B451CCC0Q36781481-F900EFA0-71DF-4C0D-90C9-C6B20906A56EQ37033512-C6E12CFF-9CC5-46B4-B97E-10CCCAC15EAEQ37094229-AA0EE992-F1C4-4389-8664-B30E06C34031Q37925813-DD5772CB-7708-4565-8E8D-F452F74EE846Q38207924-E5BF56DA-A5BE-4E31-9252-A8FB31014290Q38552894-1C96DBDE-AA76-4BA1-B2F6-1D7E823822F7Q46895816-19C9AE6E-34D1-44CA-9FE8-79A8EA1AB294Q49949305-F27EFD31-FE86-4541-AF82-A1ED95FF9FC2Q57632324-8249C666-4A07-4487-AC01-70B94C628AE6
P2860
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Population pharmacokinetics of ...... fected South African children.
@ast
Population pharmacokinetics of ...... fected South African children.
@en
type
label
Population pharmacokinetics of ...... fected South African children.
@ast
Population pharmacokinetics of ...... fected South African children.
@en
prefLabel
Population pharmacokinetics of ...... fected South African children.
@ast
Population pharmacokinetics of ...... fected South African children.
@en
P50
P1476
Population pharmacokinetics of ...... nfected South African children
@en
P2093
Doaa Elsherbiny
P2888
P304
P356
10.1007/S00228-010-0847-9
P577
2010-06-16T00:00:00Z
P5875
P6179
1007097310